title: An open-label, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra (sildenafil citrate) in Korean men with erectile dysfunction and arterial hypertension who are taking antihypertensive agents.
abstract: BACKGROUND
  Erectile dysfunction (ED) is common among men taking antihypertensive agents to control blood pressure.
  
  
  OBJECTIVE
  We evaluated the efficacy and safety of sildenafil citrate in men with ED taking antihypertensive agents.
  
  
  METHODS
  A total of 198 male subjects, aged 20 years and older were enrolled. This study was conducted for 10 weeks as an open-label, multicenter and flexible dose trial with a 2-week screening period and an 8-week treatment phase.
  
  
  METHODS
  Subjects were asked to complete Event Log Worksheets, as well as the International Index of Erectile Function (IIEF) and the Global Efficacy Assessment Questions (GEAQ) questionnaires during the study period.
  
  
  RESULTS
  The average age among the 167 subjects who completed the study was 55.8 (31.7 to 77.1). The scores for questions 3 and 4 of IIEF improved from 2.3 and 1.8 at baseline to 3.7 and 3.4 at week 4 and 3.8 and 3.4 at week 8, respectively. There were 86.3% of the patients reported improved erectile function at week 8; 88.3% of the patients reported improved ability to achieve sexual intercourse at week 8. There were no significant differences observed in the responses to questions 3 and 4 of IIEF and GEAQ by the number of antihypertensive agents taken. The adverse events were facial flushing (20.1%), headache (11.7%), palpitation (5.0%), rhinitis (2.8%), URI (2.8%), dizziness (2.2%), dyspnea (2.2%), and nausea (1.7%).
  
  
  CONCLUSIONS
  Sildenafil citrate is an effective treatment for ED; it is safe and well tolerated by patients with ED taking multiple antihypertensive agents for arterial hypertension.
authors.affiliation: Department of Urology, Pusan National University School of Medicine, Busan, Korea.
authors.forename: Hyun Jun
authors.initials: HJ
authors.lastname: Park
authors.forename: Nam Cheol
authors.initials: NC
authors.lastname: Park
authors.forename: Hong Bang
authors.initials: HB
authors.lastname: Shim
authors.forename: Jong Kwan
authors.initials: JK
authors.lastname: Park
authors.forename: Sung Won
authors.initials: SW
authors.lastname: Lee
authors.forename: Kwangsung
authors.initials: K
authors.lastname: Park
authors.forename: Sae Woong
authors.initials: SW
authors.lastname: Kim
authors.forename: Ki Hak
authors.initials: KH
authors.lastname: Moon
authors.forename: Dong Hyeon
authors.initials: DH
authors.lastname: Lee
authors.forename: Sang Jin
authors.initials: SJ
authors.lastname: Yoon
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D007723:Korea; D008297:Male; D008875:Middle Aged; D010413:Penis / Q000098:blood supply / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines / Q000627:therapeutic use; D012307:Risk Factors; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use*; D011795:Surveys and Questionnaires
chemical_list: D000959:Antihypertensive Agents; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate